X4 Pharmaceuticals expects Phase 3 mavorixafor data in chronic neutropenia in Q1 2028; enrollment to close Q4 2026

X4 Pharmaceuticals says enrollment for its Phase 3 4WARD trial of mavorixafor in chronic neutropenia is expected to conclude in Q4 2026, with top-line data in Q1 2028 and potential regulatory approval in late 2028 or early 2029; it also plans a Phase 2b trial starting in Q1 2027.

Detected & updated continuously · Source: Nebula